Global Cancer Biomarker Market Study of Future Value Chain on Revenue, Geography and Business Growth Overview 2017-2023
Global
Cancer Biomarker Market Research Report: By Types (Protein Biomarker, Genetic
Biomarker), By Applications (Diagnostic, Prognostic, Therapeutic), By End Users
(Pharmaceutical and Biotechnology Companies, Diagnostic Companies) – Forecast
till 2027
Cancer Biomarker Market Highlights
Cancer biomarkers biochemical
entities that are released during the presence of a tumor, indicating the
presence of cancer in the body. Targeting biomarkers in cancer treatment are
becoming a standard in the era of precision medicine. Market Research Future
(MRFR) has thoroughly studied the trends and patterns in the global cancer biomarker market over
the forecast period of 2017-2023 in a detailed study. MRFR asserted that the
cancer biomarker is likely to strike a CAGR of 15.8% over the forecast period.
The increasing burden of
oncological disorders has resulted in the move towards early detection and
preventive approach towards cancer. Extensive research is being carried out to
further understand the role of biomarkers and come up with new biomarkers to
predict treatment effectiveness and treatment activity in various oncology
disorders. This coupled with massive investment by both public, and private
entities have augmented the growth of the cancer biomarker market. The growing
popularity of personalized medicine is a key factor in enhancing the growth of
the cancer biomarker market. Personalized medicine hinges on biomarkers in extracting
information that is relevant for diagnosis, prognosis, and therapy and is core
to the personalized medicine field. Biomarker-driven approach can accelerate
the drug development process in cancer, and various pharmaceutical companies
are outlaying massive investments in R&D activities which are expected to
augment the growth of the market over the forecast period. Furthermore, cancer
biomarkers are an area of active research of the US FDA. Recent years have
witnessed the approval of various cancer biomarkers and has paved the way for
the expansion of the cancer biomarker market.
On the contrary, low
benefit-cost ratio associated with the development of cancer biomarkers is
likely to restrain the growth of the global cancer biomarker market.
Request
Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/5378
Segmentation
The global cancer biomarker
market has been segmented based on type, application, and end user.
By type, the cancer biomarker
market has been segmented into protein biomarker, genetic biomarker, and
others.
By application, the cancer
biomarker market has been segmented into diagnostic, prognostic and
therapeutic. The diagnostic segment has been further segmented into imaging and
non- Imaging.
By end user, the cancer
biomarker market has been segmented into pharmaceutical and biotechnology
companies, diagnostic tool companies, healthcare it/big data companies,
clinical laboratories
Regional
Analysis
By region, the cancer biomarker
market has been segmented into the Americas, Asia Pacific (APAC), Europe, and
the Middle East & Africa (MEA).
The Americas account for the
largest share of the cancer biomarker market. The high incidence rate of cancer
and rapid advances in the cancer biomarker arena to come up with new drugs and
effective therapies is supporting the growth of the market.
The Europe market is driven by
rigorous clinical trials and government funding for the same.
The influx of investment for
R&D by both public and private sector is driving the growth of the APAC
cancer biomarker market. In addition, increasing prevalence of cancer has
evoked extensive R&D activities for the development of new therapies and
drugs.
MRFR projects relatively slow
growth in the MEA cancer biomarker market. Low penetration of advanced
diagnostics and treatment facilities and lack of awareness hinders the growth
of the market.
Competitive
Landscape
F. Hoffmann-La Roche AG
(Switzerland), PerkinElmer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), Novartis
AG (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories
(U.S.), Merck & Co., Inc. (U.S.), Becton Dickinson (U.S.), Abbott
Laboratories (U.S.), Pfizer Inc. (U.S.), QIAGEN N.V (U.S.), GlaxoSmithKline
Plc. (U.S.), Illumina Inc. (U.S.), and Eli Lilly and Company (U.S.) are the
distinguished players in the cancer biomarker market.
Industry
Updates
April 2019 - Scientists at the
University of Southern California, US, are researching the presence of
polymorphisms, specific genes known for detecting the presence of cancerous
cells. The success of these findings can culminate in the use of these markers
for detecting colorectal cancer at a preventive stage.
Browse Detailed TOC with
COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/cancer-biomarker-market-5378
About
Market Research Future:
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and intelligence
services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email:
sales@marketresearchfuture.com
Comments
Post a Comment